Urtica Sp.z o.o. secures contract for Pharmaceutical products - ZP/CZD/052/26 Delivery of medicinal products and provision of repackaging and labeling services for medicinal products containing everolimus along with their release for use in the non-commercial MEDWAY clinical trial "Phase I study on the use of the CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive medulloblastoma groups 3 or 4"

Poland, July 20 -- Poland based Urtica Sp.z o.o. has secured contract from Instytut "Pomnik-Centrum Zdrowia Dziecka" for Pharmaceutical products - ZP/CZD/052/26 Delivery of medicinal products and provision of repackaging and labeling services for medicinal products containing everolimus along with their release for use in the non-commercial MEDWAY clinical trial "Phase I study on the use of the CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive medulloblastoma groups 3 or 4" . The value of the contract is worth 169037.19 PLN .

Published by HT Digital Content Services with permission from Pivotal Sources....